Ongoing Assessments & Recent Research.
Easy access to our work
Featured News & Insights.
Learn about our latest work.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
Easy access to our ongoing policy papers
ICER will evaluate selected high-impact drugs with substantial price increases that occurred in 2020. ICER will review changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be more beneficial for patients than what was previously understood.
This white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.